FLT1 rs9554320	Renal Cell Carcinoma	FLT1 rs9554320	Renal Cell Carcinoma	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B	sunitinib Sensitive: B - Late Trials sunitinib Sensitive : B
FLT1 rs9582036	Colorectal Cancer	FLT1 rs9582036	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
FLT1 elevation	Glioblastoma	FLT1 elevation	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
FLT1 overexpression	Glioblastoma	FLT1 overexpression	Glioblastoma	pembrolizumab + bevacizumab Resistant: C3 – Early Trials pembrolizumab + bevacizumab Resistant : C3	pembrolizumab + bevacizumab Resistant: C3 – Early Trials pembrolizumab + bevacizumab Resistant : C3
FLT1 overexpression	Glioblastoma	FLT1 overexpression	Glioblastoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
FLT1 mutation	Non Small Cell Lung Cancer	FLT1 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FLT1 amplification	Colorectal Cancer	FLT1 amplification	Colorectal Cancer	rivoceranib Resistant: C3 – Early Trials rivoceranib Resistant : C3	rivoceranib Resistant: C3 – Early Trials rivoceranib Resistant : C3
FLT1 expression	Renal Cell Carcinoma	FLT1 expression	Renal Cell Carcinoma	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3	sunitinib Sensitive: C3 – Early Trials sunitinib Sensitive : C3
VEGFA expression + FLT1 expression + KDR expression	Colorectal Cancer	VEGFA expression + FLT1 expression + KDR expression	Colorectal Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck	FANCI mutation + FLT1 mutation	Squamous Cell Carcinoma of Head and Neck	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3	AN2025 Sensitive: C3 – Early Trials AN2025 Sensitive : C3
FLT1 overexpression	Renal Cell Carcinoma	FLT1 overexpression	Renal Cell Carcinoma	sunitinib Sensitive: D – Preclinical sunitinib Sensitive : D	sunitinib Sensitive: D – Preclinical sunitinib Sensitive : D

FLT1 (Fms-related tyrosine kinase 1)

Associations(11)

Associations
(11)